Indonesia for Biotech / Life Sciences

Indonesia ranks #18 of 25 jurisdictions for Biotech / Life Sciences on NomadSignal's scoring model, with an industry-weighted score of 53/100. The top strengths for Biotech / Life Sciences founders are funding access and family viability. Whether it is the right choice depends on your funding stage, personal tax situation, and whether you are relocating alone or with a family.

Indonesia applies a statutory corporate tax rate of 22%. The jurisdiction has 71 active tax treaties. For Biotech / Life Sciences founders, corporate tax efficiency carries a 8% weight in the industry scoring model. Verify the current effective rate with a local advisor before making an incorporation decision.

BPOM (Indonesian FDA equivalent) is the regulatory body. Clinical trial infrastructure exists but is developing. Patent enforcement is weak. The large population provides significant clinical trial recruitment potential. Foreign-owned pharmaceutical companies face ownership restrictions. NomadSignal evaluates Biotech / Life Sciences-specific factors including Regulatory Approval Pathway, Clinical Trial Environment, Patent Regime for Biologics as part of the industry score. Check the country's official government and innovation agency websites for current program details.

Indonesia ranks #18 for Biotech / Life Sciences with 53/100. The #1 ranked jurisdiction is Singapore at 73/100. The gap is driven mainly by corporate tax, where Indonesia is weaker. Use NomadSignal's comparison pages to evaluate Indonesia head-to-head against specific alternatives.